Literature DB >> 19835152

[Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli].

Minghui Xie1, Shaowei Li, Wentong Shen, Zhongyi Li, Yudi Zhuang, Xiaobing Mo, Ying Gu, Ting Wu, Jun Zhang, Ningshao Xia.   

Abstract

Here, we presented a method to bacterially express the major structural protein L1 of Human Papillomavirus type 18 (HPV18) as soluble form. We found that the purified L1 could self-assemble to virus-like particles (VLPs). Further, we investigated the immunogenicity and the induced level of neutralizing antibody using these VLPs. First, the genome of HPV18 was cloned from a patient in Xiamen. It was used as template for PCR amplification of HPV18 L1 gene. The resultant DNA fragment was inserted into expression vector pTrxFus and expressed in Escherichia coli GI724. Second, L1 protein was purified by ammonium sulfate precipitation, ion-exchange chromatography and hydrophobic interaction chromatography; and the purified L1 was subjected to self-assembly to form VLPs with the removal of premixed reductant DTT. Finally, the size and morphology of these VLPs was investigated by Dynamic Light Scattering and Transmission Electronic Microscopy as 29.34 nm in hydrated radius and globular particles similar with native HPV18. The half effective dosage (ED50) and maximum level of neutralizing antibody elicitation were measured by vaccinations on mice, rabbit and goat using pseudovirus neutralization cell model. The results showed that the ED50 of HPV18 VLPs is 0.006 microg in mice, and the maximum titer of neutralizing antibody elicited in rabbit and goat is up to 10(7). As a conclusion, we can provide HPV18 VLPs with highly immunogenicity from prokaryote expression system, which may pave a new way for research and development of prophylactic vaccine for HPV18.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835152

Source DB:  PubMed          Journal:  Sheng Wu Gong Cheng Xue Bao        ISSN: 1000-3061


  4 in total

1.  Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.

Authors:  Hui Zhao; Zhi-Jie Lin; Shou-Jie Huang; Juan Li; Xiao-Hui Liu; Meng Guo; Jun Zhang; Ning-Shao Xia; Hui-Rong Pan; Ting Wu; Chang-Gui Li
Journal:  Hum Vaccin Immunother       Date:  2014-01-02       Impact factor: 3.452

2.  Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial.

Authors:  Yue-Mei Hu; Shou-Jie Huang; Kai Chu; Ting Wu; Zhong-Ze Wang; Chang-Lin Yang; Jia-Ping Cai; Han-Min Jiang; Yi-Jun Wang; Meng Guo; Xiao-Hui Liu; Hong-Jiang Huang; Feng-Cai Zhu; Jun Zhang; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

3.  Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Authors:  Satyavani Kaliamurthi; Gurudeeban Selvaraj; Sathishkumar Chinnasamy; Qiankun Wang; Asma Sindhoo Nangraj; William Cs Cho; Keren Gu; Dong-Qing Wei
Journal:  Viruses       Date:  2019-01-15       Impact factor: 5.048

4.  Human Papillomavirus Infection and Vaccination: Awareness and Knowledge of HPV and Acceptability of HPV Vaccine among Mothers of Teenage Daughters in Weihai, Shandong, China.

Authors:  Yang Yu; Minglei Xu; Jiandong Sun; Ruiying Li; Meilan Li; Jianguang Wang; Dongfeng Zhang; Aiqiang Xu
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.